Recently, an international group of plasma fractionators met at the 6th Annual Bioplasma World Asia Conference in Shanghai, China to discuss the latest developments in plasma-derived therapeutic production including manufacturing, regulatory affairs, and technical process innovations.
Our technical presentation at the forum focused on the two newly launched, plasma-specific Eshmuno® P affinity chromatography resins and their effective removal of anti-A and anti-B isoagglutinins from plasma therapeutic feed streams. These resins significantly contribute to enhancing patient safety without negatively impacting process economics by reusing the resins for at least 200 cycles, with acid or alkaline cleaning, and without loss of performance.
Merck Millipore + Sigma-Aldrich =
the life science business of Merck
Operating in the U.S. and Canada
To learn more about our purification solutions in plasma-derived therapeutics, visit the Plasma Learning Center.